Asia Pacific miRNA Sequencing and Assay Market
miRNA is a small noncoding RNA molecule of 20-30 nucleotides and play an important role in gene regulation. miRNA is partially complementary to messenger RNA (mRNA) and its main function is to downregulate gene expression. Since their discovery they have emerged as vital regulators of important cellular functions. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis.
Strategic insights for the Asia Pacific miRNA Sequencing and Assay provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 40.65 Million |
| Market Size by 2027 | US$ 104.82 Million |
| Global CAGR (2020 - 2027) | 12.7% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | Asia-Pacific
|
| Market leaders and key company profiles |
The geographic scope of the Asia Pacific miRNA Sequencing and Assay refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Asia Pacific miRNA sequencing and assay market is expected to reach US$ 104.82 million by 2027 from US$ 40.65 million in 2019; it is estimated to grow at a CAGR of 12.7% from 2020 to 2027. The market growth in this region is mainly attributed to the widening range of microRNA applications and rise in funding for genomics research. However, challenges related to the delivery, efficacy, and specificity of miRNA-based therapeutics hinder the market growth.
MicroRNAs (miRNAs) being involved in the process of differentiation, they act as markers in cell type identification. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. Thus, extensive research is being conducted to identify new miRNAs. Furthermore, new discoveries regarding the role of miRNAs in disease development have made them a key target of novel therapeutic approaches. Several miRNA-targeted therapeutics against the diseases such as cancer and hepatitis have reached the clinical phase. For instance, Santaris Pharma has developed a therapeutic molecule named Miravirsen that targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in the Phase II clinical trial. Therefore, rise in funding of genomic research to identify new molecules to diagnose and treat diseases, and consequent expansion of the range of applications of miRNAs are driving the growth of the miRNA sequencing and assay market in Asia Pacific.
The COVID-19 pandemic is severely affecting the countries in Asia Pacific. Disruptions in supply chains due to restrictions imposed by various countries on the transportation of goods and humans, along with the enormous demand for effective therapies for the treatment of COVID-19, have put healthcare research industry in critical situation in this region. Further, with the rise in awareness regarding the importance of miRNA sequencing and assay in COVID-19 diagnosis is propelling the demand for miRNA sequencing and assay products. Various international market players are working on the expansion of their businesses in Asia Pacific to leverage significant business potential exhibited by this region. For instance, MiRXES, Singapore, has expanded its business in Asia Pacific by establishing new subsidiary in Japan. Hence, the ongoing pandemic is contributing to the Asia Pacific miRNA sequencing and assay market growth.
The Asia Pacific miRNA sequencing and assay market, by product, is segmented into library preparation and consumables. The consumables segment held a larger share of the market in 2019, whereas the library preparation segment is anticipated to register a higher CAGR in the market during the forecast period.
Based on technology, the Asia Pacific miRNA sequencing and assay market is segmented into sequencing by synthesis, nanopore, and ion semiconductor sequencing. The sequencing by synthesis segment held the largest share of the market in 2019; however, the nanopore segment is expected to register the highest CAGR in the market during 2020–2027.
Based on end user, the Asia Pacific miRNA sequencing and assay market is segmented into research institute, academia, and CROs. The research institute segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the period.
Some of the primary and secondary sources associated with this report on the Asia Pacific miRNA sequencing and assay market are the Organization for Economic Cooperation and Development (OECD), Institute for Research in Genetic Engineering and Molecular Biology (INGBEI) and Commonwealth Scientific and Industrial Research Organization (CSIRO).
The Asia Pacific miRNA Sequencing and Assay Market is valued at US$ 40.65 Million in 2019, it is projected to reach US$ 104.82 Million by 2027.
As per our report Asia Pacific miRNA Sequencing and Assay Market, the market size is valued at US$ 40.65 Million in 2019, projecting it to reach US$ 104.82 Million by 2027. This translates to a CAGR of approximately 12.7% during the forecast period.
The Asia Pacific miRNA Sequencing and Assay Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific miRNA Sequencing and Assay Market report:
The Asia Pacific miRNA Sequencing and Assay Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific miRNA Sequencing and Assay Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific miRNA Sequencing and Assay Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific miRNA Sequencing and Assay Market
